Three-year data from the Zilver PTX randomized controlled trial of paclitaxel-eluting stents for femoropopliteal disease from Cook Medical demonstrate 70.7 percent primary patency in the superficial femoral artery (SFA) at 36 months for patients treated with the paclitaxel-eluting stent.

Surefire Medical Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its line of Surefire angiographic catheters. Surefire Medical will launch these products in the United States later this year.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now